HOME >> MEDICINE >> NEWS
7,000 Pharmaceutical scientists to share latest drug developments and discoveries

AAPS Annual Meeting Takes Place in New Orleans, November 14-18

ALEXANDRIA, Va.-- More than 7,000 pharmaceutical scientists will gather in New Orleans, November 14-18 at the 1999 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, The Quest for the Magic Bullet: An Outstanding Century. Scientists from around the world will share the latest developments in the field of pharmaceutical research and development.

"The AAPS Annual Meeting is the largest gathering of pharmaceutical scientists worldwide," said AAPS President Larry Augsburger, Ph.D. "Scientists at this meeting will present more than 2,500 contributed papers featuring important scientific findings."

The plenary session, "The Quest for the Magic Bullet: An Outstanding Century," takes place on Nov. 15, 8:30 a.m. - 12:00 p.m. The session will reflect on outstanding achievements in the pharmaceutical sciences during the 20th Century and examine how recent advances in research, development and technology will lead the pharmaceutical sciences into the next century.

"The plenary session promises to provide a glimpse into the future of drug therapy and health care and a recap of the most significant advances made in the pharmaceutical sciences over the past century," said AAPS Annual Meeting Program Chair Jay Sisco, Ph.D.

The meeting will offer nine short courses, 17 roundtables and 43 symposium sessions, which focus on topics such as the future of genetic immunization, recent developments in drug delivery and targeting, advances in vaccines, emerging analytical/bioanalytical techniques, particle engineering and modeling techniques, and competition in a patient-driven market.

Meeting highlights include:

  • 61623: Jane E. Henney, M.D., Commissioner of the Food and Drug Administration, will deliver the keynote address at the meeting's opening session on Nov. 14. Dr. Henney will outline her vision for the FDA as the agency ente
    '"/>


Contact: Amy Miller
miller@aaps.org
703--518-8417
American Association of Pharmaceutical Scientists
14-Jun-1999


Page: 1 2

Related medicine news :

1. Pharmaceutical marketing tactics hold little sway with prescribing physicians
2. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
3. Pharmaceutical Achievers
4. Pharmaceutical industry still failing health needs of less-developed countries
5. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
6. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
7. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
8. American Association of Pharmaceutical Scientists Dietary Supplements Forum examines science behind nutraceuticals
9. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
10. Pharmaceuticals and personal care products
11. New publisher announced for Journal Of Pharmaceutical Sciences

Post Your Comments:
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
Cached News: